OpenEvidence is changing the way doctors treat patients
SOPA Images/LightRocket via Getty Images
Doctors have become one of the most sought-after user bases in technology. Whether patients are aware of it or not, most physicians now use AI to guide their decision-making. They are using AI models to quickly answer clinical questions, clarify drug dosing guidelines, investigate drug interactions, and stay up to date with the latest research studies. A wave of companies and venture capitalists are racing to take advantage of this trend.
The Money Pouring In
Capital is quickly moving into the healthcare technology market. One example is OpenEvidence. The company first raised outside funding in February 2025 with $75 million from Sequoia at a $1 billion valuation. From there, the valuation climbed rapidly and participation broadened. OpenEvidence is now valued at $12 billion following a $250 million Series D round co-led by Thrive Capital and DST Global in January 2026.
OpenEvidence, an AI platform that helps doctors find evidence-based answers to clinical questions by searching trusted medical journals, isn’t the only company attracting investor interest in medical AI. Hippocratic AI, which builds AI agents for clinical and administrative tasks, secured $126 million at a $3.5 billion valuation. Ambience Healthcare, which offers a broader AI healthcare operating system, raised $243 million in 2025. And in the narrower clinical-workflow niche specifically, AvoMD raised $10 million in March 2026.
Competition In Clinical AI
Before OpenEvidence, the clinical reference market was dominated by a handful of subscription incumbents, such as UpToDate, DynaMed, and ClinicalKey. Each was backed by a large publisher. Nearly all of them have now layered generative AI onto their existing products rather than cede the category to venture-backed newcomers.
UpToDate Expert AI, owned by publisher Wolters Kluwer, launched in October 2025. It generates conversational answers grounded exclusively in UpToDate’s editorial content, with stated assumptions, inline links, and built-in Continuing Medical Education (CME) credits. Reviewers who cover the market consistently rank it as the strongest expert-authored reference assistant by brand trust and content depth. However, a price point of roughly $530 per year for an individual U.S. subscriber is well above OpenEvidence’s free model.
Dyna AI/DynaMed, owned by EBSCO, started in July 2024 after 18 months of beta testing. It draws exclusively from EBSCO’s curated content, monitors more than 250 medical journals, maintains over 100,000 citations, and is generally regarded as the most transparent in the group for evidence grading, using the established GRADE framework.
ClinicalKey AI is another major competitor in the space. Owned by Elsevier, the Dutch publishing and data analytics company, the product is used by more than 300 hospitals. The tool delivers point-of-care clinical answers by analyzing daily-updated full-text articles and practice guidelines from over 1,000 peer-reviewed medical journals. It also adds real-time citation verification and traceability so clinicians can trace exactly which passage of source material produced a given answer.
Of all the competitors in the clinical decision arena, hospital-built systems and vertical integration may be the most consequential long-term threat to every standalone vendor. Industry analysts point to Epic and Oracle Health as the biggest competitive risk, given their ability to build AI query capabilities directly into existing electronic health record systems, allowing AI-generated answers to surface within clinicians’ workflows rather than in a separate app they have to open.
Finally, a wave of free, ad- or grant-supported entrants is crowding in as well, with newer names like Vera Health, Glass Health, Doximity Ask, and AMBOSS AI Mode all courting the same physician user base that built OpenEvidence’s early lead. The fight for doctors’ eyeballs is clearly accelerating.
Risks In Clinical Decision AI Tools
Beyond product-level accuracy concerns associated with any AI support tool, the market carries risks that extend past any single company.
As with most areas in healthcare, the regulatory risk is real. On January 6, 2026, the FDA issued updated final guidance on clinical decision support software that reduces oversight for tools whose recommendations a clinician can independently review and understand, provided those recommendations aren’t the primary basis for a clinical decision. But the same guidance draws a sharper line for tools that cross that threshold. Software intended for critical, time-sensitive decisions generally doesn’t qualify for the lighter-touch exemption.
Another risk is liability. While AI tools have taken on a larger role in clinical decision-making, the legal responsibility hasn’t shifted with them. Physicians remain on the hook if they lean too heavily on an AI-generated recommendation. Both users and providers of AI clinical software have to navigate different laws at the federal and state level.
Competition from general-purpose LLMs is another significant risk. New health-information products from OpenAI and Anthropic are examples of how frontier AI labs building general-purpose assistants pose a persistent threat to any company whose moat depends on being the best interface to medical knowledge, rather than on owning genuinely proprietary data or clinical distribution.
Outlook For The Clinical Reference Market
As in other areas of the AI landscape, clinical reference tools are here to stay. “I believe LLMs have become another indispensable clinical tool much like the stethoscope, EKG, or ultrasound,” says Dr. Aviv Katz, a Gastroenterologist based in Palm Beach, Florida. “In the near future, I expect their use to become part of the standard of care. I would question the physician who chooses not to use them.”
Doctors clearly want this kind of tool. What’s less certain is who delivers it, and how. The eventual winners will be the ones that combine an interface doctors actually want to use with answers that are accurate, timely, well-cited, and trusted.
OpenEvidence currently holds the lead, with more than 40% of physicians using the product, but many new competitors are on its heels. In addition, publishers like Elsevier and Wolters Kluwer are aggressively defending decades of institutional trust and licensing relationships.
These stand-alone AI tools have to compete with the giant medical record firms, Epic and Oracle, which hold more than 65% of the combined market share and can fold AI copilots directly into existing clinical workflows.
For now, capital continues to flow into the clinical reference market as AI adoption grows. What’s less certain is which logo will still be on the product doctors use once the fight for market share is over.